Clinical Trials
396
37 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1837
Active, not recruiting
22
5.6%
Approved For Marketing
1
0.3%
Completed
226
57.1%
Enrolling By Invitation
4
1.0%
No Longer Available
1
0.3%
Not yet recruiting
11
2.8%
Recruiting
46
11.6%
Suspended
1
0.3%
Terminated
39
9.8%
Unknown
2
0.5%
Withdrawn
43
10.9%
No approval data available
- The MIND diet, which combines elements of Mediterranean and DASH diets, has more research supporting its role in dementia prevention than any other dietary approach currently studied. - A 2024 Lancet report estimated that 45% of dementia cases worldwide are caused by modifiable risk factors, with diet playing a significant role alongside exercise, sleep, and social engagement. - Key MIND diet foods include leafy greens, berries, nuts, olive oil, and fatty fish; one study found daily leafy green consumption was associated with brain function equivalent to being 11 years younger. - Experts emphasize that sustainable long-term habits matter more than perfection, and diet works best when combined with physical activity, adequate sleep, and social connection.
- NeuraLight completed PALOMA, a 12-month multicenter study with 300 Parkinson's patients, representing one of the largest longitudinal trials using eye-movement biomarkers to track disease progression. - The study demonstrated that NeuraLight's eye-movement biomarkers correlate significantly with standard clinical assessments like MDS-UPDRS and MoCA, with 10x more sensitivity than current gold standards. - The platform's 10-minute tablet-based assessment offers a more objective and scalable approach to monitoring Parkinson's progression compared to traditional clinical tools. - Results suggest this technology could transform neurological drug development by providing more sensitive and repeatable measurements for clinical trials.
- Neuren Pharmaceuticals has dosed the first patient in its landmark Koala Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, marking the first-ever Phase 3 study for this rare neurodevelopmental disorder. - Published Phase 2 data showed statistically significant improvements across 10 of 14 efficacy assessments, including communication, behavior, and quality of life measures in 18 children with PMS. - The Phase 3 trial has received regulatory approval from both the FDA and Health Canada, with plans to enroll approximately 160 children aged 3-12 years across multiple sites. - NNZ-2591 has been granted Fast Track, Rare Pediatric Disease, and Orphan Drug designations by the FDA, highlighting the urgent unmet medical need for PMS treatments.
- The FDA has granted Breakthrough Therapy Designation to adrabetadex for infantile-onset Niemann-Pick disease type C, based on survival analyses showing improved outcomes compared to external controls. - Adrabetadex directly addresses the underlying pathology of NPC by re-establishing intracellular cholesterol trafficking, marking a potential therapeutic breakthrough for this devastating neurodegenerative disorder. - Beren Therapeutics plans to submit a New Drug Application in the near future, with the drug expected to be eligible for Priority Review given its orphan drug status. - The designation represents a significant regulatory milestone for a disease with extremely poor prognosis, where early-infantile-onset cases have a mean survival of approximately 5.6 years.
- Onkos Surgical received FDA 510(k) clearance for its ELEOS Proximal Tibia with NanoCept Antibacterial Technology, marking the first 510(k) clearance for NanoCept since its original De Novo authorization in April 2024. - The NanoCept technology demonstrated up to 99.999% bacterial kill rate in preclinical studies, offering a proactive approach against intraoperative bacterial contamination in orthopaedic implants. - The ELEOS Proximal Tibia with NanoCept is part of the company's limb salvage system designed for patients with significant bone loss due to cancer, trauma, or previous surgical procedures. - The clearance extends NanoCept technology to one of the most challenging anatomical sites for bone tumors and complex bone loss, with over 350 leading US academic medical institutions using Onkos products.
- The FDA has granted approval for Nobles Medical Technology II to restart its pivotal NobleStitch clinical trial, evaluating the first device-free, suture-mediated system for patent foramen ovale closure to reduce recurrent cryptogenic stroke. - The trial was proactively paused by CEO Dr. Anthony Nobles to enhance safety standards and protocol robustness, with patient enrollment expected to resume in Q4 2025. - The NobleStitch EL system uses proprietary percutaneous suturing to close intracardiac defects without permanent implants, potentially reducing complications from conventional metal mesh occluders including nickel hypersensitivity. - Rush University Medical Center has been added as a new clinical site under Dr. Josh Murphy's direction, with the company planning to submit a Pre-Market Approval application upon study completion.
- Rush University Medical Center will begin the world's first clinical study in July 2025 integrating Apple Vision Pro with Medtronic's GI Genius AI module for real-time colonoscopy guidance. - The innovative system allows physicians to view AI-generated polyp detection insights directly in their field of vision without looking away from the procedure screen. - The study results will support Cosmo Pharmaceuticals' planned FDA submission for what could become the first FDA-cleared medical software application on Apple Vision Pro. - The GI Genius AI module has already demonstrated the ability to increase adenoma detection rates by up to 14.4% in colorectal cancer screening procedures.
- Pykus Therapeutics has completed enrollment for its PYK-2101 pilot study in Australia, testing a first-in-class biodegradable retinal hydrogel sealant for retinal detachment surgery. - The innovative treatment aims to eliminate the need for post-operative face-down positioning and intraocular gas, potentially transforming patient recovery and surgical outcomes. - The company plans to submit an Investigational Device Exemption application to the FDA in Q4 2025 for a U.S. pivotal trial, with interim study results expected in Q2 2025.
- JointMedica has commenced an Investigational Device Exemption study for its Polymotion® Hip Resurfacing System, designed to address challenges faced by younger, active patients requiring hip replacement. - The innovative system features a metal-on-plastic bearing instead of traditional metal-on-metal surfaces, potentially expanding treatment options for women who were previously excluded from hip resurfacing procedures. - The IDE study has launched at seven prestigious clinical sites across the United States and Bermuda, with renowned orthopedic surgeons evaluating the system's safety and effectiveness.
- New research published in Menopause reveals that higher leukocyte counts are strongly associated with increased severity of long COVID symptoms in older postmenopausal women. - The study analyzed data from over 1,200 Women's Health Initiative participants, finding that white blood cell count serves as an independent predictor of post-acute sequelae of SARS-CoV-2 infection (PASC) severity. - This discovery could transform diagnosis and treatment approaches for long COVID, offering healthcare providers a widely available, inexpensive clinical marker to identify at-risk patients.
